Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Teduglutide - Takeda

X
Drug Profile

Teduglutide - Takeda

Alternative Names: ALX-0600; Gattex; Revestive; TAK 633; Teduglutide - Shire

Latest Information Update: 27 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Toronto General Hospital; University of Toronto
  • Developer Shire; Takeda; Takeda Pharmaceuticals International GmbH
  • Class Anti-inflammatories; Peptides
  • Mechanism of Action Glucagon-like peptide 2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Short bowel syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes - Crohn's disease

Highest Development Phases

  • Marketed Short bowel syndrome
  • Suspended Crohn's disease
  • No development reported Mucositis

Most Recent Events

  • 29 Feb 2024 Registered for Short bowel syndrome in China (SC), before February 2024 (Takeda pipeline, May 2024)
  • 27 Sep 2023 Takeda completes a phase III trial in Short bowel syndrome (In infants, In children, In adolescents, In adults, In the elderly) in Japan (SC) (NCT05027308)
  • 01 Jun 2022 The National Institute for Health and Care Excellence (NICE) recommends teduglutide, once daily subcutaneous injection, as an option for people living with Short bowel syndrome (SBS) (In infants, In children, In adolescents, In adults, In the elderly) in United Kingdom

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top